- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 05.11. | hVIVO PLC - Presentation at Jefferies London Healthcare Conf | 1 | RNS | ||
| 11.10. | hVIVO PLC - Long Term Incentive Plan/ PDMR Notification | - | RNS | ||
| HVIVO Aktie jetzt für 0€ handeln | |||||
| 07.10. | hVIVO upbeat on positive human challenge trial results with client | 1 | Sharecast | ||
| 07.10. | hVIVO PLC - Positive results from RSV human challenge trial | 1 | RNS | ||
| 30.09. | hVIVO gets HSE clearance, launches new lab services | 2 | Sharecast | ||
| 30.09. | hVIVO PLC - Launch of full suite of hLAB standalone services | - | RNS | ||
| 10.09. | hVIVO hails "record" half-year revenue, as profit soars 70% higher | 2 | Alliance News | ||
| 10.09. | Clinical trial specialist hVivo's H1 revenues jump by 30% | 1 | RTE.ie | ||
| 10.09. | hVIVO PLC - Interim results | 1 | RNS | ||
| 20.08. | hVIVO PLC - Notice of results | 2 | RNS | ||
| 05.08. | JD Wetherspoon chair offloads 1% stake while hVIVO chair exits the register | Directors Deals | 1 | Shares | ||
| 05.08. | Life sciences firm hVIVO cancels Euronext listing to focus on London | 1 | City A.M. | ||
| 05.08. | Three Quick Facts: UK Oil & Gas, Clarkson, hVIVO | 1 | The Armchair Trader | ||
| 05.08. | hVIVO PLC - Euronext cancellation | - | RNS | ||
| 23.07. | hVIVO PLC - Director/PDMR Shareholding | - | RNS | ||
| 17.07. | hVivo expects half year revenues to rise by 30% | 1 | RTE.ie | ||
| 17.07. | hVIVO reports 31% revenue jump; relocation to improve efficiencies | 1 | Alliance News | ||
| 17.07. | Hvivo delivers record revenues in H1, reiterates FY guidance | 1 | Sharecast | ||
| 17.07. | hVIVO PLC - Trading update | - | RNS | ||
| 02.07. | hVIVO secures biggest field study contract to date | 2 | Sharecast |
Seite:
1 2 Weiter >>
26 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PLUS THERAPEUTICS | 1,154 | 0,00 % | Plus Therapeutics Inc.: Plus Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights | Obtained agreement from FDA to initiate a Phase 1 trial evaluating multiple doses of Rhenium (186Re) Obisbemeda for the treatment of patients with leptomeningeal metastases (LM) Presented positive... ► Artikel lesen | |
| SPINEWAY | 0,084 | 0,00 % | Spineway: a week dedicated to medical excellence with more than 20 surgeons trained | ||
| ASENSUS SURGICAL | 0,305 | 0,00 % | KARL STORZ akquiriert den US-amerikanischen Robotik-Spezialisten Asensus Surgical | Tuttlingen / Research Triangle Park, USA (ots) - Das familiengeführte und international agierende Medizintechnikunternehmen KARL STORZ gibt die Akquisition des innovativen Robotik-Spezialisten Asensus... ► Artikel lesen | |
| MEDIVOLVE | 0,003 | 0,00 % | Medivolve Inc (2): Medivolve president, CEO Preiner resigns | ||
| LIFEWARD | 1,840 | 0,00 % | Lifeward Ltd.: Coverage for ReWalk Personal Exoskeleton Expands as Hungary Joins the U.S. and Germany with a Policy Providing Access to Exoskeletons | ||
| JD HEALTH | 3,440 | -1,15 % | JD Health-Aktie gewinnt 2,37 Prozent (3,46 €) | Der Anteilsschein von JD Health notiert heute etwas fester. Zuletzt zahlten Investoren für das Wertpapier 3,46 Euro. Das Wertpapier von JD Health verzeichnet zur Stunde einen Wertanstieg von 2,37 Prozent.... ► Artikel lesen | |
| EKSO BIONICS | 0,718 | +6,53 % | Ekso Bionics stock plunges to 52-week low of $0.71 | ||
| IMUNON | 0,620 | -4,62 % | Imunon, Inc.: IMUNON Presents Positive Data from Phase 2 OVATION 2 Clinical Trial of IMNN-001 in Advanced Ovarian Cancer at SITC 39th Annual Meeting | IMNN-001 immunotherapy plus standard-of-care chemotherapy resulted in 35% improvement in overall survival and 25% improvement in progression-free survival versus standard-of-care alone Treatment was... ► Artikel lesen | |
| ROCKWELL MEDICAL | 2,212 | +0,27 % | Rockwell Medical-Direktor Mark H. Ravich verkauft Aktien im Wert von 70.379 US-Dollar | ||
| AVINGER | 0,770 | 0,00 % | Avinger-Aktie erreicht 52-Wochen-Tief bei 0,75 US-Dollar | ||
| VIRIDIAN THERAPEUTICS | 18,800 | 0,00 % | Viridian Therapeutics Reports Third Quarter 2024 Financial Results and Recent Progress Including New FcRn Data | WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering and developing potential best-in-class medicines for serious and rare... ► Artikel lesen | |
| SINTX TECHNOLOGIES | 3,720 | 0,00 % | SINTX Technologies, Inc.: SINTX Technologies Provides Positive Strategic Business Update for Q3 2024 | Salt Lake City, UT, Nov. 14, 2024 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ: SINT) ("SINTX" or the "Company"), an advanced ceramics company that develops and commercializes materials, components... ► Artikel lesen | |
| AETHLON MEDICAL | 0,328 | 0,00 % | AETHLON MEDICAL INC - S-8, Securities to be offered to employees in employee benefit plans | ||
| STAGEZERO LIFE SCIENCES | 0,028 | -100,00 % | StageZero Life Sciences Ltd: StageZero Life Sciences Announces Update on Filing of Full Year 2023 Financials Under the Failure To File Cease Trade Order | TORONTO, ON / ACCESSWIRE / July 9, 2024 / StageZero Life Sciences, Ltd. (TSX:SZLS)(OTC PINK:SZLSF) ("StageZero" or the "Company"), an integrated healthcare company with the first and only mRNA gene... ► Artikel lesen | |
| NEURONETICS | 0,723 | +6,32 % | Greenbrook Receives Final Court Approval For Arrangement With Neuronetics |
HVIVO PLC gehört der Branche Gesundheitswesen an. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 0,236 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu HVIVO PLC finden Sie auf Wallstreet Online.
